Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma

Journal of Hematology and Oncology

Volumn 1, Issue 1, 2008, Pages

  Tate Jr , David J ^a   Vonderhaar, Derek J ^a   Caldas, Yupanqui A ^b   Metoyer, Toye ^c   Patterson IV, John R ^a   Aviles, Diego H ^d   Zea, Arnold H ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; DRUG DERIVATIVE; N(OMEGA) HYDROXYNORARGININE; N(OMEGA)-HYDROXYNORARGININE;

ANIMAL; ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA CELL LINE; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD3; ARGINASE; ARGININE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; JURKAT CELLS;

EID: 71449119332     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-1-14     Document Type: Article

References (46)

1. Brittenden J, Heys SD, Ross J, Park KG, Eremin O: Nutritional pharmacology: effects of L-arginine on host defences, response to trauma and tumour growth. Clin Sci (Lond) 1994, 86:123-132. (Pubitemid 24056691)
2. Albina JE, Caldwell MD, Henry WL Jr, Mills CD: Regulation of macrophage functions by L-arginine. J Exp Med 1989, 169:1021-1029. (Pubitemid 19085837)
3. Ochoa JB, Strange J, Kearney P, Gellin G, Endean E, Fitzpatrick E: Effects of L-arginine on the proliferation of T lymphocyte subpopulations. JPEN J Parenter Enteral Nutr 2001, 25:23-29. (Pubitemid 32057755)
4. Wu G, Morris SM Jr: Arginine metabolism: nitric oxide and beyond. Biochem J 1998, 336(Pt 1):1-17. (Pubitemid 28532555)
5. Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 1982, 243:C212-C221. (Pubitemid 13250914)
6. Miyanaka K, Gotoh T, Nagasaki A, Takeya M, Ozaki M, Iwase K, Takiguchi M, Iyama KI, Tomota K, Mori M: Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem J 1998, 30:741-751. (Pubitemid 28551805)
7. Bernard A, Kasten M, Meier C, Manning E, Freeman S, Adams W, Chang P, Boulanger B, Kearney P: Red blood cell arginase suppresses Jurkat (T cell) proliferation by depleting arginine. Surgery 2008, 143:286-291.
8. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, Luckner C, Doschko G, Soler G, Eichmann K, Muller FM, Ho AD, Goerner M, Modolell M: Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 2005, 105:2549-2556. (Pubitemid 40387058)
9. Gotoh T, Araki M, Mori M: Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem Biophys Res Commun 1997, 233:487-491. (Pubitemid 27226654)
10. Braissant O, Gotoh T, Loup M, Mori M, Bachmann C: L-arginine uptake, the citrulline-NO cycle and arginase II in the rat brain: an in situ hybridization study. Brain Res Mol Brain Res 1999, 70:231-241. (Pubitemid 29317637)
11. Jenkinson CP, Grody WW, Cederbaum SD: Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol 1996, 114:107-132. (Pubitemid 26234050)
12. Bernard AC, Mistry SK, Morris SM Jr, O'Brien WE, Tsuei BJ, Maley ME, Shirley LA, Kearney PA, Boulanger BR, Ochoa JB: Alterations in arginine metabolic enzymes in trauma. Shock 2001, 15:215-219. (Pubitemid 33599105)
13. Jacob TD, Ochoa JB, Udekwu AO, Wilkinson J, Murray T, Billiar TR, Simmons RL, Marion DW, Peitzman AB: Nitric oxide production is inhibited in trauma patients. J Trauma 1993, 35:590-596.
14. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmas A, O'Neill A, Mier J, Ochoa AC: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048. (Pubitemid 40524582)
15. Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, Cederbaum SD: Cloning and characterization of the human type II arginase gene. Genomics 1996, 38:118-123. (Pubitemid 26424589)
16. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G: Arginase activity in human breast cancer cell lines: N(omega)hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000, 60:3305-3312. (Pubitemid 30407931)
17. Buga GM, Wei LH, Bauer PM, Fukuto JM, Ignarro LJ: NG-hydroxyL-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am J Physiol 1998, 275:R1256-R1264.
18. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW: Expression of arginase II in prostate cancer. Int J Oncol 2008, 32:357-365. (Pubitemid 351188302)
19. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003, 171:1232-1239. (Pubitemid 36900052)
20. Deignan JL, Livesay JC, Yoo PK, Goodman SI, O'Brien WE, Iyer RK, Cederbaum SD, Grody WW: Ornithine deficiency in the arginase double knockout mouse. Mol Genet Metab 2006, 89:87-96. (Pubitemid 44205470)
21. Iyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, O'Brien WE, YU H, Grody WW, Cederbaum SD: Mouse model for human arginase deficiency. Mol Cell Biol 2002, 22:4491-4498. (Pubitemid 34620387)
22. Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton HM, Wiltrout RH: Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype. Cancer Res 2001, 61:6255-6263. (Pubitemid 32762565)
23. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995, 1:1327-1335.
24. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF, Ochoa AC: Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis 2006, 194:1385-1393. (Pubitemid 44706506)
25. Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, DeSalvo J, Ochoa JB, Park HJ, Zabaleta J, Ochoa AC: L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol 2004, 232:21-31. (Pubitemid 40732717)
26. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK: Arginases I and II: do their functions overlap? Mol Genet Metab 2004, 81(Suppl 1):S38-S44. (Pubitemid 38402233)
27. Kepka-Lenhart D, Mistry SK, Wu G, Morris SM Jr: Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am J Physiol Regul Integr Comp Physiol 2000, 279:R2237-R2242.
28. Wei LH, Wu G, Morris SM Jr, Ignarro LJ: Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc Natl Acad Sci (USA) 2001, 98:9260-9264. (Pubitemid 32743904)
29. Li H, Meininger CJ, Kelly KA, Hawker JR Jr, Morris SM Jr, Wu G: Activities of arginase I and II are limiting for endothelial cell proliferation. Am J Physiol Regul Integr Comp Physiol 2002, 282:R64-R69. (Pubitemid 34663912)
30. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, Kropf P, Mueller I, Kolb A, Modolell M, Ho AD: Suppression of T-cell functions by human granulocyte arginase. Blood 2006, 108:1627-1634. (Pubitemid 44316131)
31. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G: Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001, 280:E75-E82.
32. Murphy C, Newsholme P: Importance of glutamine metabolism in murine macrophages and human monocytes to L-arginine biosynthesis and rates of nitrite or urea production. Clin Sci (Lond) 1998, 95:397-407. (Pubitemid 28474725)
33. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Bouche JL: Effects of the new arginase inhibitor N (omega)-hydroxy-nor-Larginine on NO synthase activity in murine macrophages. Nitric Oxide 1999, 3:427-438. (Pubitemid 30070642)
34. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A: Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005, 201:1257-1268. (Pubitemid 40629069)
35. Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, Cederbaum SD, Ignarro LJ: Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996, 271:H1988-H1998.
36. Scott L, Lamb J, Smith S, Wheatley DN: Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 2000, 83:800-810.
37. Philip R, Campbell E, Wheatley DN: Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. Br J Cancer 2003, 88:613-623. (Pubitemid 36363373)
38. Wheatley DN, Campbell E: Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilization of citrulline by malignant cells. Br J Cancer 2003, 89:573-576. (Pubitemid 37026445)
39. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH: Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deaminase. Int J Cancer 2007, 120:897-905.
40. Bronte V, Zanovello P: Regulation of immune responses by Larginine metabolism. Nat Rev Immunol 2005, 5:641-654. (Pubitemid 41113195)
41. Baniyash M: TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004, 4:675-687. (Pubitemid 39223074)
42. Taheri F, Ochoa JB, Faghiri Z, Culotta K, Park HJ, Lan MS, Zea AH, Ochoa AC: L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res 2001, 7:958s-965s. (Pubitemid 33600951)
43. Selamnia M, Mayeur C, Robert V, Blachier F: α- difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochemical Pharmacology 1998, 55:1241-1245. (Pubitemid 28206713)
44. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H: Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice. Cancer Res 2000, 60:5125-5133.
45. Simoneau AR, Gerner EW, Nagle R, Argyrios Ziogas A, FujikawaBrooks S, Hagit Yerushalmi H, Ahlering TE, Lieberman R, Christine E, McLaren CE, Anton-Culver H, Frank L, Meyskens FL Jr: The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiology Markers 2008, 17:292-299. (Pubitemid 351272778)
46. Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ: Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 2003, 20:271-281. (Pubitemid 37193939)